Apheresis Science

Join Us, Follow and Share

Last-Generation Drugs

Join Us, Follow and Share

Lipoprotein apheresis

Global Scientific Society

Join Us, Follow and Share

Meetings and educational events

Join us, follow and share

MIGHTY MEDIC

Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast

Benvenuti nel sito web di MIGHTY MEDIC, il Gruppo Multidisciplinare dedicato alle terapie aferetiche nell’ambito delle patologie metaboliche ed alla loro applicazione in combinazione con i farmaci di ultima generazione.

Welcome into the web site of MIGHTY MEDIC, the Multidisciplinary Group dedicated to apheresis therapies for the treatment of metabolic pathologies and their application in combination with last-generation drugs.

Foundation Act

MIGHTY MEDIC: Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances

Il Gruppo MIGHTY MEDIC vuole riunire specialisti di differenti discipline biomediche al fine di condividere progetti, divulgare aggiornamenti sulle patologie dismetaboliche

Scientific Board: Dr. Mariko HARADA-SHIBA M.D., Ph.D. Prof. Dr. Med. ULRICH JULIUS Prof. CLAUDIA STEFANUTTI, M.D., Ph.D.

MULTIDISCIPLINARY INTERNATIONAL GROUP FOR HEMAPHERESIS THERAPY AND METABOLIC DISTURBANCES CONTRAST

Implementing American Heart Association Pediatric and Adult Nutrition Guidelines

A Scientific Statement From the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research Read More

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

Studyquestion: Are differences in androgen levels among women with various forms of ovarian dysfunction associated with cardiometabolic abnormalities? summaryanswer: Androgen levels differed substantially between women with and without ovarian dysfunction, and increased androgen levels were associated with impaired cardiometabolic features in all women irrespective of their clinical condition. what is …

Statin Intolerance: Diagnosis and Remedies

Abstract Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, …

Ezetimibe plus simvastatin for the treatment of hypercholesterolemia

Introduction: Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with statins or alone, but its role …

Ten-Year Follow-up After Initiation of Statin Therapy in ChildrenWith Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is a prevalent (1:500 individuals) inherited disorder that strongly predisposes to premature atherosclerosisandsubsequent cardiovascular disease. In children with FH, atherosclerosis progression is observed before puberty. Consequently, guidelines for FH treatment advocate initiation of statins in childrenasyoung as8 years. However, longterm efficacy and safety data for statin therapy initiated during childhood do not exist.We …

FH-CTA Consortium

About FT-CTA

Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9-Inhibitors, Lipoprotein Apheresis or both?

Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9-Inhibitors, Lipoprotein Apheresis or both? Nephrologisches Zentrum GöttingenGbR Priv. Doz. Dr.med. V. Schettler

NORMARE LA PATOLOGIA GENETICAMENTE DETERMINATA IPERLp (a)LIPOPROTEINEMIA CHE SI ASSOCIA AD ALTO RISCHIO CARDIOVASCOLARE

Giovedì 12 Maggio 2016 AUDITORIUM MINISTERO DELLA SALUTE Lungotevere Ripa, 1 ROMA La diffusione della malattia in Italia ed nel Lazio La prevalenza storica, rispettivamente della Ipercolesterolemia Familiare (IF) Omozigote ed Eterozigote è di 1: 1000000 e di 1:500. In Italia circa 2200 ragazzi sotto i 14 anni soffrono …

WAA/SFH Joint Congress, Paris, 27–29 April 2016

11th LIPIDCLUB 2016 The MIGHTY MEDIC Gobal Scientific Society

11th LIPIDCLUB 2016 The MIGHTY MEDIC Gobal Scientific Society

[slideshow_deploy id=’1008′]

World Congress on Clinical Lipidology 10 – 12 February, 2017 Brisbane, Australia

EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA

Authors: John J.P. Kastelein, Gisle Langslet, Paul Hopkins, Joep Defesche, Werner Seiz, Marie Baccara-Dinet, Sara Hamon, Poulabi Banerjee, Claudia Stefanutti, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, Sanofi, Montpellier, France Background: Next Generation Sequencing was performed to examine treatment response with alirocumab in patients carrying one or more causative mutation(s) in five familial …

Efficacy of Alirocumab in 1191 Patients with a Wide Spectrum of Mutations in Genes Causative for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of developing premature coronary heart disease. The prevalence of heterozygous and homozygous FH has been estimated to be 1:200 to 1:500 and 1:160,000 to 1:1,000,000, respectively. In plasma, LDL-C levels are regulated via apolipoprotein …

The third annual congress of the Association for Preventive Pediatrics Serbia with international participation

“PREVENTION IN PEDIATRICS – BASIS FOR HEALTHY LIFE AND LONGEVITY” 15 – 17 April 2016. Hotel Holiday Inn, Belgrade

Serbia Assoc of Peds

Serbia Assoc of Peds: Final Program [slideshow_deploy id=’1019′]

Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia.

http://www.ncbi.nlm.nih.gov/pubmed/19927363

Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study.

http://www.ncbi.nlm.nih.gov/pubmed/20091936

Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia.

The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55 ± 9.3 years …

New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.

http://www.ncbi.nlm.nih.gov/pubmed/22963620

Lipoprotein apheresis: state of the art and novelties

http://www.ncbi.nlm.nih.gov/pubmed/23357136

Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances

http://www.ncbi.nlm.nih.gov/pubmed/25410046

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

http://www.ncbi.nlm.nih.gov/pubmed/25881720

The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.

http://www.ncbi.nlm.nih.gov/pubmed/25965722

Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.

http://www.ncbi.nlm.nih.gov/pubmed/25950706

Hypercholesterolemia Family “Today we can intervene effectively in children”

“L’ipercolesterolemia familiare – spiega la dottoressa Guardamagna, pediatra dell’Università di Torino – è una condizione ereditaria che si correla con un elevato rischio di eventi cardiovascolari che si manifestano di solito in età adulta, anche se il soggetto non ha in precedenza manifestato sintomi specifici. Diverso il caso dei soggetti …

Lipoprotein (a): when the apheresis is the right solution.

Il Prof. Dr. med. Ulrich Julius, Professore di Medicina/Malattie Metaboliche del Dipartimento di Medicina Interna III, Università Ospedaliera Carl Gustav Cerus presso l’Università Tecnica di Dresda, spiega il ruolo della lipoproteina (a) e le possibilità terapeutiche per i pazienti affetti da ipercolesterolemia.
L’intervista al Prof. Julius è stata realizzata da Osservatorio Malattie Rare il 18 Dicembre 2015 in occasione dell’incontro “Lipoprotein apheresis; verso una consensus: integrare la lipoprotein apheresis con i nuovi farmaci ipolipemizzanti ”, organizzato dalla prof.ssa Claudia Stefanutti e dalla società scientifica Mighty Medic, che quello stesso giorno ha firmato il proprio atto ufficiale di costituzione.

Lomitapide: less apheresis and quality of life

La dottoressa Morozzi lavora al Policlinico Umberto I al fianco della professoressa Claudia Stefanutti, Responsabile dell’U.O.Tecniche Terapeutiche Extracorporee. Il gruppo della professoressa Stefanutti ogni settimana tratta con aferesi delle lipoproteine circa 30 pazienti di ogni età affetti da dislipidemia su base genetica. “Grazie all’uso del farmaco Lomitapide – spiega la …

Born in Rome the International Scientific Society ‘Mighty Medic’

Il 18 Dicembre scorso a Roma è stato firmato l’atto costitutivo della società scientifica internazionale Migthy Medic. “Obiettivo della società – spiega la prof.ssa Claudia Stefanutti, Responsabile dell’U.O.Tecniche Terapeutiche Extracorporee – Centro per lo Studio, Diagnosi e Terapia delle Dislipidemie e Prevenzione della Aterosclerosi – Dipartimento di Medicina Molecolare “Sapienza” …

EAS International Lp(a) Satellite Meeting – Innsbruck, 27-28/05/2016

http://lpa.i-med.ac.at/index.html

European Atherosclerosis Society – Innsbruck, 29/05-01/06/2016

http://eas2016.kenes.com/

Apheresis Science

Join Us, Follow and Share

Join Us, Follow and Share

Global Scientific Society

Meetings and educational events

MIGHTY MEDIC

Foundation Act

What is MIGHTY MEDIC

Scientific Board

Global Scientific Society